Endpoints in Preclinical Alzheimer’s Disease Trials
J Clin Psychiatry 2014;75(6):661–662
© Copyright 2015 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
Researchers, pharmaceutical companies, funders, regulators, and other stakeholders in the scientific fight against Alzheimer’s disease have expressed great interest in the evaluation of putative “preclinical Alzheimer’s disease treatments,” interventions that are initiated in cognitively unimpaired persons and intended to postpone, reduce the risk of, or completely prevent progression to the clinical stages of Alzheimer’s disease. Thank goodness. With the growing number of persons living to older ages, preclinical Alzheimer’s disease treatments are urgently needed to avert a catastrophic public health problem, and at least some of the proposed treatments may need to be initiated before the mild cognitive impairment (MCI) or dementia stages of Alzheimer’s disease, when the pathology is already extensive, to be most efficacious.